216 related articles for article (PubMed ID: 32979066)
1. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
[TBL] [Abstract][Full Text] [Related]
2. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
Bone; 2024 Jun; 186():117164. PubMed ID: 38871265
[TBL] [Abstract][Full Text] [Related]
3. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab.
Hattori K; Kanayama Y
Mod Rheumatol; 2024 Feb; ():. PubMed ID: 38300506
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
[TBL] [Abstract][Full Text] [Related]
5. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
[TBL] [Abstract][Full Text] [Related]
6. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
Ebina K; Nagayama Y; Kashii M; Tsuboi H; Okamura G; Miyama A; Etani Y; Noguchi T; Hirao M; Miura T; Fukuda Y; Kurihara T; Nakata K; Okada S
Osteoporos Int; 2024 May; 35(5):841-849. PubMed ID: 38296866
[TBL] [Abstract][Full Text] [Related]
7. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment.
Nakamura Y; Suzuki T; Kato H
Ther Clin Risk Manag; 2017; 13():1343-1348. PubMed ID: 29062234
[TBL] [Abstract][Full Text] [Related]
8. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.
Everts-Graber J; Wenger M; Oser S; Studer U; Steiner C; Ziswiler HR; Sromek K; Schmid G; Gahl B; Häuselmann H; Reichenbach S; Lehmann T
Osteoporos Int; 2024 Jun; ():. PubMed ID: 38922397
[TBL] [Abstract][Full Text] [Related]
9. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
[TBL] [Abstract][Full Text] [Related]
10. Bone loss and new vertebral fractures during treatment with romosozumab: a case-report.
Marsman AF; de Jongh RT; Teunissen BP; Lems WF
Arch Osteoporos; 2024 Jan; 19(1):10. PubMed ID: 38238593
[TBL] [Abstract][Full Text] [Related]
11. Association of osteoporosis and high serum homocysteine levels with intraoperative periprosthetic fracture during total hip arthroplasty: a propensity-score matching analysis.
Watanabe N; Ogawa T; Takada R; Amano Y; Jinno T; Koga H; Yoshii T; Okawa A; Miyatake K
Arch Orthop Trauma Surg; 2023 Dec; 143(12):7219-7227. PubMed ID: 37468711
[TBL] [Abstract][Full Text] [Related]
12. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
Kumar S; Gild ML; McDonald MM; Kim AS; Clifton-Bligh RJ; Girgis CM
Osteoporos Int; 2024 Jun; ():. PubMed ID: 38839655
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta.
Dattagupta A; Petak S
AACE Clin Case Rep; 2023; 9(6):209-212. PubMed ID: 38045794
[TBL] [Abstract][Full Text] [Related]
14. Increased bone resorption that outpaces increased bone formation: An important pathology of rapidly destructive coxarthrosis.
Watanabe N; Ogawa T; Miyatake K; Takada R; Jinno T; Koga H; Yoshii T
J Orthop Res; 2024 May; 42(5):1066-1073. PubMed ID: 38044471
[TBL] [Abstract][Full Text] [Related]
15. Number of contiguous vertebral cross-links in the spine indicates bone formation: a cross-sectional study.
Furukawa M; Shibata R; Okuyama K
BMC Musculoskelet Disord; 2023 Sep; 24(1):736. PubMed ID: 37715167
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Romosozumab in Primary Care.
Hye Yang S; Mittal N; Bell AL; Bell CE
J Pharm Technol; 2024 Jun; 40(3):152-157. PubMed ID: 38784024
[No Abstract] [Full Text] [Related]
17. A practical approach for anabolic treatment of bone fragility with romosozumab.
Cianferotti L; Cipriani C; Palermo A; Viapiana O; Zavatta G; Mazziotti G
J Endocrinol Invest; 2024 May; ():. PubMed ID: 38789679
[TBL] [Abstract][Full Text] [Related]
18. Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa.
Fujimoto K; Maki N; Hashiba D; Maeyama T; Nakagawa R; Arai H; Ohtori S
Osteoporos Sarcopenia; 2023 Dec; 9(4):137-141. PubMed ID: 38374824
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.
Bovijn J; Krebs K; Chen CY; Boxall R; Censin JC; Ferreira T; Pulit SL; Glastonbury CA; Laber S; Millwood IY; Lin K; Li L; Chen Z; Milani L; Smith GD; Walters RG; Mägi R; Neale BM; Lindgren CM; Holmes MV
Sci Transl Med; 2020 Jun; 12(549):. PubMed ID: 32581134
[TBL] [Abstract][Full Text] [Related]
20. Changes in Testing and Treatment Methods in Osteoporosis Care.
Nagai T; Ishikawa K; Tsuchiya K; Tani S; Dodo Y; Oshita Y; Sakamoto K; Kawate N; Kudo Y
J Osteoporos; 2024; 2024():9629891. PubMed ID: 38659619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
